Welcome to our dedicated page for Retractable Technologies news (Ticker: RVP), a resource for investors and traders seeking the latest updates and insights on Retractable Technologies stock.
Retractable Technologies, Inc. reports developments tied to its safety medical products business, including VanishPoint® syringes, blood collection and IV catheter products, Patient Safe® syringes, and EasyPoint® retractable needles. The company manufactures and markets devices designed to reduce needlestick injuries, product reuse, and catheter-related contamination risks, with distribution through specialty and general line medical distributors.
Recurring news themes for RVP include operating results, domestic and international sales trends, product mix shifts involving EasyPoint® needles, tariff exposure on products imported from China, and changes in manufacturing activity as the company expands domestic production where practical. Updates also cover workforce reductions, product designations, and dividends on Series II and Series III Class B Convertible Preferred Stock.
Retractable Technologies, Inc. (RVP) announced dividends for Series II Class B and Series III Class B Convertible Preferred Stock, amounting to $39,050.00 and $19,061.25 respectively. The dividends, accrued at $1.00 per share per annum, cover the period from January 1, 2022, to March 31, 2022. Payment is scheduled for April 21, 2022, to shareholders of record as of April 11, 2022. The company specializes in safety medical products designed to reduce needlestick injuries and bloodstream infection risks.
Retractable Technologies, Inc. (RVP) declared dividends for its Series II Class B and Series III Class B Convertible Preferred Stock totaling $39,050.00 and $39,495.10. The dividends accrued at $1.00 per share per annum. The Series II dividends cover October 1, 2021, to December 31, 2021, while the Series III dividends cover July 1, 2021, to December 31, 2021. Payment is scheduled for January 24, 2022, to shareholders of record as of January 10, 2022.
Retractable Technologies, Inc. (NYSE American: RVP) reported significant improvement in financial performance for the first nine months of 2021, with operating income rising to $44.1 million compared to $11.8 million in the previous year. Income applicable to common shareholders also surged to $35.0 million from $14.7 million. Net sales reached $36.4 million for Q3 2021, driven largely by orders from the U.S. government, which accounted for over 50% of total sales. Despite revenue increases, gross margins were pressured by rising transportation costs due to COVID-19 impacts.
Retractable Technologies, Inc. (NYSE American: RVP) has declared dividends of $39,050 for its Series II Class B Convertible Preferred Stock, equating to $0.25 per share. The accrued dividends at 10% per annum cover amounts from July 1, 2021 to September 30, 2021. Payment is scheduled for October 22, 2021, to shareholders on record as of October 12, 2021. This announcement highlights the company's commitment to its investors, despite potential operational risks and external market challenges.
Retractable Technologies, Inc. (NYSE American: RVP) reported a significant increase in operating income, reaching $36.1 million for the first six months of 2021, up from $1.4 million in the prior year. Income applicable to common shareholders was $28.5 million, compared to $3.7 million the previous year. Net sales for the quarter ended June 30, 2021, were $42.5 million, with the U.S. government accounting for 64.4% of sales. Domestic revenues surged 325.0%, driven by increased government orders.
Retractable Technologies, Inc. (RVP) has approved a stock repurchase plan for up to $10 million, starting June 18, 2021. This plan will run until June 18, 2022, and is designed to enhance shareholder value in response to the stock's perceived undervaluation. The company will also distribute $5,056,945 in dividends to its Class B Convertible Preferred shareholders, including amounts in arrears, with payments scheduled for July 22, 2021. CEO Thomas J. Shaw acknowledged shareholder patience and highlighted the company's commitment to providing essential safety products.
Retractable Technologies, Inc. (RVP) announced an amendment to delivery order 75A50120F33003 from the Department of Health and Human Services, extending the performance end date from May 2021 to March 2022. The amendment reallocates orders to increase shipments of 1mL low dead-space safety syringes. The total contract price and freight costs remain unchanged. The company emphasizes potential challenges, including COVID-19 impacts, liquidity issues, and foreign trade risks among others, that could affect future performance.
Retractable Technologies, Inc. (NYSE American: RVP) has received preliminary notice from the U.S. Department of Health and Human Services to exercise all seven one-month option periods under contract 75A50121P00021, extending the contract's expiration to February 14, 2022. This extension increases the contract's value by $92,772,680, covering products and freight reimbursement costs.
Retractable Technologies Inc. (NYSE American: RVP) has amended its Technology Investment Agreement with the U.S. government, securing an additional $27.4 million in funding. This increase aims to boost domestic manufacturing capabilities by at least 50% to meet ongoing COVID-19 countermeasure demands. The funding will be used to expand production of 1mL low dead-space safety syringes by adding new assembly lines and expanding facilities in Little Elm, Texas. The modification effort is scheduled to be completed by January 31, 2022.
Retractable Technologies, Inc. (NYSE American: RVP) reported a significant increase in operating income to $23.4 million for Q1 2021, a sharp rise from $481 thousand a year prior. U.S. government sales accounted for 75.5% of total revenues, highlighting a 484.7% increase in domestic sales. Additionally, the company had its $1.36 million PPP loan forgiven. However, operating expenses increased 50%, driven by higher headcount and related costs. Overall, domestic unit sales surged 282.6%, although international revenues decreased by $1.5 million.